During the Trading Day
|9.31|| -0.02 / -0.21%|
As of 3:59pm ET
|8.79|| -0.52 / -5.59%|
Novavax, Inc. is a clinical-stage biopharmaceutical company, which engages in development of novel recombinant vaccines to address a broad range of infectious diseases. The company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles and recombinant nanoparticle vaccines. Its product pipeline targets a variety of infectious diseases and currently has completed clinical trials that target pandemic influenza (H5N1), seasonal influenza and Respiratory Syncytial Virus. Novavax was founded in 1987 and is headquartered in Gaithersburg, MD.
|There are no executives to display.|